Supplements Companies Are Cashing In on the Ozempic Wave

  • 📰 WIRED
  • ⏱ Reading Time:
  • 15 sec. here
  • 5 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 51%

Science News

Health,Drugs,The Age Of Ozempic

With demand for GLP-1 drugs sky-high, the supplement industry is elbowing into the market. Some products are meant to complement meds like Ozempic. Others are positioned as “natural” alternatives.

Two different types of supplements are glomming onto the popularity of GLP-1 agonist drugs like semaglutide and tirzepatide, which mimic a natural appetite-suppressing, blood-sugar-regulating hormone called glucagon-like peptide-1. First, there’s a rise in efforts to market supplements as complementary to GLP-1 drugs.

Supergut CEO Marc Washington told WIRED that the company’s sales in 2024 were three to four times previous years’ sales as a result of increased interest in non-pharmaceutical ways to increase GLP-1 production. Some health experts question whether these offerings are worthwhile.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 555. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: ForbesTech - 🏆 318. / 59 Read more »

Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: Forbes - 🏆 394. / 53 Read more »

For companies in the Ozempic-fueled weight-loss economy, it's survival of the fittestAs powerful anti-obesity drugs become more widely available, companies are repositioning themselves with new products and services.
Source: latimes - 🏆 11. / 82 Read more »